Page 584 - The Case Lab Book

sees the acquisition of under maximised drug pricing as an

opportunity to raise prices and is willing to cover this by

passing the blame onto the insurance companies as they

fight with the medical fraternity over copay responsibilities.

Shkreli’s MSMB company was less than successful and his

ventures into senior management at Retrophin, Turing and
KaloBios was likewise short lived and contentious. In some

senses he acted as a corporate raider stepping in acquiring

drugs to hike their prices.